NGL Fine Chem Ltd Q2 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
Yes
Capex
Yes
3 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 2- The company anticipates consistent growth over the next 3-5 years by adding new products from their existing pipeline.
- Plans to commercialize 3 new products this year and 3-4 products next calendar year, aiming for a product basket of 27-30 within two years.
- Targets to reach a quarterly revenue run rate of Rs. 100-110 crores within the next two to two-and-a-half years, driven by increased outsourcing, Macrotech expansion, and process debottlenecking.
- Greenfield expansion at Tarapur (50% capacity addition) expected to commercialize by mid-FY24, funded by Rs. 100 crores CAPEX.
- Market opportunities for top 10 products estimated at Rs. 400-500 crores annually.
- Focus remains on niche molecules with sufficient pipeline to keep growth intact.
- Confident of maintaining and growing market share in key products and geographies including Latin America, Africa, and the US.
See what NGL Fine Chem Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company plans a Greenfield expansion at Tarapur with an expected CAPEX of Rs. 100 crores.
- This CAPEX will be funded through a mix of debt and internal accruals.
- No specific mention of new equity fundraising or IPO plans related to this expansion.
- The company is currently net debt-free, indicating a strong balance sheet to support funding.
- The Board has decided to proceed with listing on the NSE, with the listing process expected to complete within 6-8 months, but this is not explicitly linked to fresh fundraising.
See what NGL Fine Chem Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Macrotech expansion: Rs. 28 crores already incurred; awaiting final approvals; expected commercialization in next few weeks; will increase intermediate manufacturing capacity and contribute to revenues from Q4 onwards.
- Greenfield expansion at Tarapur: Planned Capex of Rs. 100 crores, bringing 50% capacity addition; approvals and land are in place; construction to start soon (contractor selection in progress); expected to commercialize and start production by mid FY24.
- Expansion funded through mix of debt and internal accruals.
- Aim to increase outsourced production to 15%.
- Ongoing efforts in debottlenecking and process improvements to drive near-term growth.
- Construction costs initially higher due to metal and equipment price increases; expected to moderate as metal prices stabilize.
Track NGL Fine Chem Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- The company expects to reach a quarterly revenue run rate of around ₹100-110 crores within the next two years, driven by Macrotech expansion, increased outsourcing, and debottlenecking efforts.
- EBITDA margins currently at about 23%, with potential downside of up to 5% if raw material prices remain high; margins expected to recover quickly if prices stabilize.
- Long-term margin range anticipated between 18-25%, influenced more by macroeconomic factors than internal changes.
- Net profit for Q2 FY22 was ₹14 crores with an 18% margin; future margins may stay under pressure for the next four quarters due to high costs.
- The company plans a ₹100 crore Greenfield expansion at Tarapur, expected to add 50% capacity by mid-FY24, supporting further growth.
- Overall, with strong demand and capacity expansions, sustained profit growth and stable margins are expected over the medium term.
Order book
Yes- The company does not explicitly mention a specific current order book value in the transcript.
- Rahul Nachane indicates strong and growing demand, with no risk of losing orders due to capacity constraints.
- They are increasing outsourcing and expanding capacity (Macrotech expansion and Greenfield project) to meet demand.
- Outsourcing optimization expected around May/June next year.
- Aim to reach approximately Rs. 100 crore quarterly run rate in 2 to 2.5 years, indicating a robust order pipeline.
- Confident about continuing sales growth and market share gains.
- They have sufficient capacity levers and do not anticipate supply issues impacting order fulfillment.
How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does NGL Fine Chem Ltd rank in Pharmaceuticals & Biotechnology?
Compare NGL Fine Chem Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY22) on revenue, margins and earnings-call signals.
Continue your research
What NGL Fine Chem Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…